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Background: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction
of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study
was to determine the effect of tofacitinib on patient-reported outcomes (PROs).
Methods: Eligible patients (≥18 years of age) with a diagnosis of active UC (total Mayo score of 6-12 points and
moderately-to-severely active disease on sigmoidoscopy) were randomized in a 2:2:2:3:3 ratio to receive oral
tofacitinib 0.5 mg, 3 mg, 10 mg, or 15 mg, or placebo twice daily (BID) for 8 weeks. PROs were assessed by the
Inflammatory Bowel Disease Questionnaire (IBDQ) and the Inflammatory Bowel Disease Patient-Reported Treatment
Impact (IBD PRTI) survey.
Results: At Week 8, mean IBDQ total scores had improved relative to baseline across all five treatment groups
(baseline range 123.2-134.5; Week 8 range 149.6-175.4). Improvement from baseline was significantly greater
(P = 0.001) for tofacitinib 15 mg BID versus placebo. For tofacitinib 15 mg BID, most patients reported satisfaction
or extreme satisfaction, definite preference for tofacitinib, and definite willingness to use tofacitinib again on the
IBD PRTI at week 8. Patients achieving endoscopic remission (Mayo endoscopy score of 0) had significantly higher
IBDQ scores and favorable PRTI scores than those not achieving endoscopic remission.
Conclusions: Short-term treatment with tofacitinib BID was associated with dose-dependent improvement in
health-related quality of life and patient preferences for tofacitinib. The results complement previously reported
efficacy and safety data for the Phase II study. (NCT 00787202, November 6, 2008).
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In North America the highest annual incidence of UC is re-
ported to be 19.2 per 100,000 person-years, in Europe 24.3,
and 6.3 in Asia and the Middle East [1]. Current medical
therapies for ulcerative colitis (UC) are only effective in a
proportion of patients and for patients who fail to respond,
surgery is often necessary. A study of Canadian patients
with UC calculated approximately one-tenth of patients will
have a colectomy within 10 years of diagnosis and one-
sixth within 20 years of diagnosis [2].
Tofacitinib (CP-690,550) is a novel, oral small molecule
Janus kinase (JAK) inhibitor that is being investigated for* Correspondence: JPANES@clinic.ub.es
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unless otherwise stated.use in several inflammatory diseases, including UC. In kin-
ase assays, tofacitinib preferentially inhibits signaling by
receptors associated with JAK3 and JAK1 while it demon-
strates reduced inhibition for JAK2- and tyrosine kinase 2
(TYK2)-associated signaling [3]. JAKs mediate signal trans-
duction activity by the surface receptors for multiple cyto-
kines. Importantly, tofacitinib directly inhibits signaling for
an important subset of pro-inflammatory cytokines includ-
ing IL-2, -4, -7, -9, -15, and -21 [3,4]. These cytokines are
integral to lymphocyte activation, proliferation, and func-
tion, and inhibition of their signaling may result in modula-
tion of multiple aspects of the immune response [3-6].
In an 8-week Phase II randomized controlled trial (RCT)
in patients with moderately-to-severely active UC (clinical-
trials.gov NCT00787202), treatment with tofacitinib wasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in clinical response and clinical remission compared with
placebo. Definitions of remission and response have been
described previously [7].
Patient-reported outcomes (PROs) represent an inte-
gral and increasingly important aspect of drug develop-
ment as a complementary measure of efficacy because
they represent direct measures of patient-perceived
benefit. The Inflammatory Bowel Disease Questionnaire
(IBDQ) has been used in many trials and is generally
accepted as providing valuable additional information
regarding the efficacy of treatment for patients with UC.
The outcome can be measured in absolute terms (e.g.,
severity of a symptom, sign, or state of the disease) or as
a change from a previous measure. The Inflammatory
Bowel Disease Patient-Reported Treatment Impact (IBD
PRTI) survey asks about patient’s overall satisfaction
with their current treatment and overall willingness to
initiate and continue the treatment versus their previous
treatment.
To evaluate the effect of tofacitinib on health-related
quality of life (HRQoL) and patient preferences for tofaci-
tinib, we report for the first time a distinct set of PROs
from the 8-week Phase II RCT. We further report on the
relationship between the PROs of the IBDQ and the IBD
PRTI. The relationship between these PROs and the Mayo
score-based clinical and endoscopic outcomes were also
analyzed.Methods
Patients
Eligible patients were ≥18 years of age and had a diag-
nosis of UC for ≥3 months before study entry, had ac-
tive disease defined by a Mayo score of 6-12 points (in
which scores range from 0 to 12 with higher scores indi-
cating more severe disease) [8], and moderately-to-
severely active disease on sigmoidoscopy. Patients could
receive oral mesalamine and/or oral corticosteroids at a
stable dose of ≤30 mg per day of prednisone equiva-
lence. Exclusion criteria, permitted medications, and
prohibited concomitant medications have previously
been described [7].Study design
This 8-week, multicenter, Phase II RCT was conducted
at 51 centers in 17 countries between January 2009 and
September 2010. Patients were randomly assigned in a
2:2:2:3:3 ratio to receive oral tofacitinib at doses of 0.5
mg, 3 mg, 10 mg, or 15 mg, or placebo administered
twice daily (BID). Patients were treated for 8 weeks and
followed for a further 4 weeks. The randomization
process and primary efficacy and safety evaluations have
previously been described in full [7].PRO instruments
PROs were assessed by the IBDQ and the 3-item IBD
PRTI (Version 2) survey. These PROs were pre-defined
secondary efficacy measures in the study protocol. The
IBDQ is a psychometrically validated instrument for
measuring disease-specific HRQoL in patients with IBD,
including UC [9]. The IBDQ comprises 32 items which
are grouped into four domains: bowel function, emotional
status, systemic symptoms, and social function. The four
domains are scored as follows: bowel symptoms, 10 to 70;
systemic symptoms, 5 to 35; emotional function, 12 to 84;
and social function: 5 to 35. With 1 to 7 points for each
item, the total score on this index ranges from 32 to 224,
with higher scores indicating better HRQoL [10]. IBDQ
response has been defined as an increase in IBDQ total
score of ≥16 points from baseline, and remission has been
defined as a total IBDQ score of ≥170 points [9]. The
IBDQ was self-completed by patients at baseline (Day 1)
and at Week 8.
The IBD PRTI survey (Additional file 1) comprises three
individual questions concerning patient satisfaction with
study treatment, patient preference for study drug over prior
treatment (this question on subject preference for study
medication is prefaced by a simple question about previous
treatments for IBD in order to place the preference question
into context), and patient willingness to reuse the study
treatment again. Each of the three questions (the fourth
question on previous treatment was for information only)
was scored on a 5-point scale. Patients completed the survey
at the end of the study (Week 8), or at early withdrawal
from the study. The IBD PRTI is a measure for assessing pa-
tient satisfaction, patient preferences for study treatments,
and willingness to use treatment again. The utility of asses-
sing these concepts within clinical trials has been demon-
strated by several authors [11-14].
Clinical evaluation
As previously reported [7], disease activity of patients with
UC was measured using the Mayo scoring system [8]. The
full Mayo system consists of four subscores, each graded
from 0 to 3 points, with higher scores indicating more se-
vere disease. Total scores per patient range from 0 to 12
points. The four subscores are: stool frequency, rectal
bleeding, findings of flexible sigmoidoscopy, and physician
global assessment. Clinical response was defined as
a decrease in Mayo score from baseline of ≥3 points
and ≥30%, with an accompanying decrease in the subscore
for rectal bleeding of ≥1 point or an absolute subscore for
rectal bleeding of 0 or 1. Clinical remission was defined as
a total Mayo score of ≤2 points, with no individual sub-
score exceeding 1 point, and endoscopic remission was
defined as a Mayo endoscopic subscore of 0. The partial
Mayo score is a non-invasive outcome measure based on
three of the four full Mayo subscores and lacks the
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scale of 0 to 9.
During the trial, the total Mayo score was assessed at
baseline and Week 8 and the partial Mayo score was
assessed at baseline and Weeks 2, 4, and 8.
Statistical analysis
Pre-specified
The primary efficacy endpoint of the Phase II study was
based on the total Mayo score clinical response at Week
8. The IBDQ, IBD PRTI, and partial Mayo score we report
were pre-specified secondary efficacy analyses.
The analysis of clinical response and clinical remission
at Week 8 was performed using a maximal efficacy (Emax)
model with treatment group as a factor and a term in-
cluded for prior anti-tumor necrosis factor therapy. Pa-
tients with data missing for reasons other than insufficient
response to therapy or an adverse event related to UC
were excluded from the analysis. All IBDQ data for the
four domains and total score were summarized by time
post-dose for each dose. The Week 8 change from base-
line for each dose was analyzed using an analysis of co-
variance that allowed for variation due to dose group and
baseline value. The individual IBD PRTI items were
scored separately. Missing IBDQ and IBD PRTI data were
not replaced.
The full analysis set (FAS) was the primary analysis set
for all efficacy analyses and included all randomized pa-
tients who had either withdrawn as a treatment failure or
had completed at least 1 week of dosing and had at least
one valid Mayo score during the active double-blind phase
of the study. The intention-to-treat population analysis
classified all patients with missing Week 8 data as non-
responders.
Post-Hoc analyses
We performed a series of supplemental (post-hoc) calcula-
tions using all available data (by pooling all treatment
groups) to evaluate relationships between the IBDQ, the
Mayo scale (full and partial),the Mayo endoscopy sub-
score, and the IBD PRTI survey. No imputation of missing
data was performed.
Relationships between the IBDQ and the Mayo scores
were examined using a repeated measures longitudinal
model [15,16]. The Mayo score was used as a continuous
predictor in the modeling. By doing so, the linear relation-
ship was effectively imposed between the outcome and
predictor. In another series of models, considered as sensi-
tivity analyses, the Mayo score was used as a categorical
predictor. This approach did not impose any functional
relationship between the predictor and outcome. If a lin-
ear or approximately linear relationship was realized be-
tween the IBDQ and the Mayo score, the Mayo score as a
continuous predictor would be more sensitive and moreeasily interpretable. The relationship between the IBD
PRTI score and the Mayo score at Week 8 was examined
using a regression model. In one set of models, the Mayo
score was a continuous predictor and in another set, the
Mayo score was a categorical predictor.
Pearson correlations between IBDQ score and Mayo
score, and between IBD PRTI and Mayo score, were cal-
culated. A two-by-two contingency table on remission
status is provided (Additional file 2).
Ethical considerations
The study was performed in compliance with the Dec-
laration of Helsinki and the International Conference on
Harmonisation Good Clinical Practice Guidelines, and
was approved by the Institutional Review Boards at each
study center. All patients provided written informed
consent. The full names of every Institutional review
board that approved the study in each center is provided
in Additional file 3.
Results
Demographics
Patient demographic and baseline disease characteristics
have been described previously [7]. Briefly, a total of 195
patients were randomized and 194 received study drug: 48
patients in the placebo group and 31, 33, 33, and 49 in the
tofacitinib groups received 0.5 mg, 3 mg, 10 mg, and 15
mg BID, respectively. A total of 157 of the 194 patients
(80.9%) completed the study (Additional file 4). The one
patient who did not receive the study drug (in the placebo
group) was excluded from the analyses. The demographics
and baseline disease characteristics of the five groups were
similar, with only the proportion of patients using a gluco-
corticoid at baseline being significantly different (P < 0.05)
across treatment groups [tofacitinib 0.5, 3, 10, and 15 mg
BID; n = 11 (35%), 10 (30%), 19 (58%), 13 (27%), respect-
ively, versus placebo, 13 (27%)].
IBDQ
Mean IBDQ total scores (FAS, non-imputation population)
at baseline were similar between treatment groups, ranging
from 123.8 to 134.5 in the tofacitinib groups (123.2 in the
placebo group). At Week 8, mean IBDQ total scores had
improved (higher scores indicate better quality of life) across
all treatment groups compared to baseline, ranging from
149.6-175.4 in the tofacitinib groups (151.3 in the placebo
group) (Table 1). The adjusted mean change (improvement)
from baseline was significantly greater (P= 0.001) at Week 8
for tofacitinib 15 mg BID versus placebo (Figure 1). A trend
towards a dose-response was observed in the IBDQ scores.
Statistically significant (P < 0.05) improvements in mean
change from baseline were observed across all four IBDQ
domains, with the greatest improvements in patients in
the tofacitinib 15 mg BID group (Table 1). A logistic
Table 1 IBDQ total scores (FAS), IBDQ domain score (FAS), and percentage of patients achieving clinically meaningful




0.5 mg (N = 31) 3 mg (N = 33) 10 mg (N = 33) 15 mg (N = 49)
IBDQ total score (SD)
Baseline, n 47 31 30 31 48
Mean 123.2 (29.5) 123.8 (34.5) 132.3 (33.6) 134.5 (32.5) 124.0 (34.9)
Week 8, n 34 18 26 28 43
Mean 151.3 (33.4) 149.6 (37.7) 166.6 (42.4) 160.5 (33.7) 175.4 (35.3)
Mean change from baseline 27.8 (29.8) 27.7 (33.4) 30.3 (27.3) 30.4 (39.8) 50.7 (35.6)#
Mean change from baseline in IBDQ domains (SD)
Week 8, n 34 18 24 26 42
Bowel function 9.15 (10.59) 11.06 (10.48) 11.46 (9.65) 13.19 (14.18) 18.96 (11.60)#
Emotional status 9.49 (11.89) 6.33 (14.09) 9.21 (10.60) 7.88 (14.70) 16.48 (14.75)#
Systemic symptoms 4.44 (5.86) 4.89 (5.81) 4.79 (4.62) 3.85 (6.39) 7.24 (5.88)#
Social function 4.67 (6.49) 5.44 (7.45) 4.83 (5.72) 5.46 (6.96) 8.04 (7.07)#
IBDQ responsea/remissionb
Week 8, n 48 31 33 33 49
Patients with Clinically meaningful IBDQ response, n (%) 20 (41.7) 12 (38.7) 14 (42.4) 16 (48.5) 37 (75.5)
Logistic regression odds ratioa (95% CI) Referent 0.84 (0.33–2.13) 1.05 (0.42–2.60) 1.27 (0.52–3.11) 4.18* (1.75–10.02)
Patients with IBDQ remission, n (%) 11 (22.9) 8 (25.8) 14 (42.4) 12 (36.4) 30 (61.2)
Logistic odds ratioc (95% CI) Referent 1.12 (0.39–3.23) 2.56 (0.96–6.80) 1.87 (0.70–4.99) 5.23** (2.14–12.75)
Range of IBDQ total score = 32-224. Maximal domain score: Bowel function = 70; Emotional status = 84; Systemic symptoms = 35; Social function = 35.
#P <0.05 versus placebo (ANCOVA).
*P = 0.001, **P < 0.001: odds ratio versus placebo (logistic regression).
aClinically meaningful IBDQ response = ≥16 point improvement in total IBDQ score.
bIBDQ remission = total IBDQ score of ≥170 at Week 8.
cversus placebo.
BID, twice daily; CI, confidence interval; FAS, full analysis set; IBDQ, Inflammatory Bowel Disease Questionnaire; ITT, intention-to-treat population where patients
with missing Week 8 data were treated as non-responders; NA, not applicable.
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fidence interval [CI], 1.75–10.02) for patients receiving
tofacitinib 15 mg BID to achieve a clinically meaningful
IBDQ response (≥16-point improvement in total IBDQ
score) at Week 8 versus placebo. Similarly, the odds ratio
over the same time period for patients achieving IBDQ re-
mission (total IBDQ score of ≥170) was also statistically
significant for tofacitinib 15 mg BID (5.23 [95% CI, 2.14–
12.75]; P < 0.001) (Table 1).
IBD PRTI
For each of the three component items of the IBD PRTI
(patient global satisfaction, patient global preference, and
patient willingness to use the drug again), dose-related im-
provements were observed that were greatest in patients
receiving tofacitinib 15 mg BID (Table 2). IBD PRTI com-
ponent frequency distributions at Week 8 also highlighted
treatment-related preferences for tofacitinib such that, for
tofacitinib 15 mg BID, the majority of patients reported
satisfaction or extreme satisfaction, a definite preference
for tofacitinib over previous treatments, and a definite
willingness to use tofacitinib again (Figure 2).Correlation between PROs and Mayo score based
outcomes
The correlations between the IBDQ total score versus the
total Mayo score, the partial Mayo score, and the Mayo
endoscopic subscore were all consistent, in the expected dir-
ection (with a lower Mayo score corresponding to a higher
IBDQ score), and approximately linear (Figure 3A-C). A 1-
point change on the total Mayo score corresponded, on
average, to a change of 8.0 (P < 0.0001) points on the IBDQ
total score. The correlation at baseline was 0.33, and at
Week 8, 0.62 (P < 0.0001) (Figure 3A). A 1-point change on
the partial Mayo score corresponded, on average, to a
change of 10.8 (P < 0.0001) points on the IBDQ total score.
The correlation at baseline was 0.32, and at Week 8, 0.64
(P < 0.0001) (Figure 3B). Patients achieving endoscopic re-
mission (Mayo endoscopy score of 0) had an IBDQ total
score significantly higher (P < 0.0001) than patients without
endoscopic remission. The differences in the IBDQ total
scores between patients with, versus patients without, endo-
scopic remission were 45.7 when a linear relationship was
imposed in modeling and 41.8 when the Mayo endoscopy





























0.5 mg 3 mg 10 mg 15 mg
*
(n=34) (n=18) (n=24) (n=26) (n=42)
Tofacitinib BID
Figure 1 Adjusted mean change from baseline (SE) in total IBDQ score at Week 8. A higher score indicates better quality of life. The
ANCOVA model used treatment group as a factor and the baseline value as a covariate. The center was not included in the model. *p = 0.001
compared with placebo (analysis of covariance). BID, twice daily; IBDQ, inflammatory bowel disease questionnaire; SE, standard error.
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moderate (0.46, P < 0.0001). . We found a significant correl-
ation between the bowel domain subscore of IBDQ and the
two domains of the Mayo score considered as PROs:
stool frequency (r = -0.55, p < 0.0001), rectal bleeding
score (r = -0.56, p < 0.0001), and the combined stool fre-
quency and rectal bleeding score (r = -0.64, p < 0.0001)
at week 8. The corresponding correlations at week 0
were smaller (r = 0.31. r = 0.27 and r = 0.39 respectively,
all p < 0.001) due to the restricted range of data.
Furthermore, when the IBD PRTI components for all
patients were modeled against the total Mayo score
(Figure 4A-C), the partial Mayo score (Additional file 5),
and the Mayo endoscopy subscore (Figure 5A-C) all correla-
tions were consistent, in the right direction, and approxi-
mately linear. For the total Mayo score, a 1-point change
corresponded to a mean change in Patient PreferenceTable 2 IBD PRTI scores at Week 8 (observed population)





0.5 mg (n =
Patient global satisfactiona 3.2 (0.2) 3.2 (0.3)
Patient global preferenceb 2.8 (0.2) 2.6 (0.3)
Patient willingness to use drug againc 2.3 (0.2) 2.8 (0.3)
aExtremely dissatisfied with study drug = 1, Dissatisfied with study drug = 2, Neither
Extremely satisfied with study drug = 5.
bDefinitely prefer study drug over prior treatment = 1, Slightly prefer study drug = 2
prior treatment = 5.
cWould definitely use study drug again = 1, Might use study drug again = 2, Not sur
drug again = 5.
BID, twice daily; PRTI, IBD Patient-Reported Treatment Impact (Version 2) survey; SEAssessment of 0.24 points (P < 0.0001), 0.26 points in Pa-
tient Satisfaction Assessment (P < 0.0001) and 0.24 points in
Patient Willingness Assessment (P < 0.0001) if a model with
imposed linear relationship between IBD PRTI item score
and the total Mayo score is used. Correlation at Week 8 be-
tween the IBD PRTI item scores and the total Mayo score
were moderate-to-high: 0.59 (P < 0.0001; Patient Preference
Assessment), 0.70 (p < 0.0001; Patient Satisfaction Assess-
ment), and 0.60 (p < 0.0001; Patient Willingness Assess-
ment) (Figure 4A-C).
For partial Mayo score, a 1-point change corresponded to
a mean change of: 0.31 points (P < 0.0001; patient preference
assessment), 0.34 points (P < 0.0001; patient satisfaction
assessment), and 0.32 points (P < 0.0001; patient willingness
assessment) if a model with imposed linear relationship be-
tween the IBD PRTI item score and the partial Mayo score
was used. Correlation at Week 8 between IBD PRTI itemID
29) 3 mg (n = 33) 10 mg (n = 31) 15 mg (n = 47)
3.5 (0.2) 3.7 (0.2) 4.3 (0.1)
2.4 (0.2) 2.2 (0.2) 1.5 (0.1)
2.4 (0.2) 2.2 (0.2) 1.6 (0.1)
satisfied nor dissatisfied with study drug = 3, Satisfied with study drug = 4,
, No preference = 3, Slightly prefer prior treatment = 4, Definitely prefer
















































































































































































































































































Figure 2 IBD PRTI score frequency distributions at Week 8 (FAS). BID, twice daily; PRTI, IBD patient-reported treatment impact (version 2) questionnaire.
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Figure 3 Relationship between the IBDQ total score (all patients) versus the total Mayo score (a), the Mayo partial score (b), and the
Mayo endoscopic subscore (c).
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Figure 4 Relationship between the components of the IBD PRTI (all patients) including patient satisfaction (a), preference (b), and willingness
(c) versus the total Mayo score. IBD PRTI item scores: Patient satisfaction assessment; Extremely dissatisfied with study drug = 1, Dissatisfied with study
drug = 2, Neither satisfied nor dissatisfied with study drug = 3, Satisfied with study drug = 4, Extremely satisfied with study drug = 5. Patient preference
assessment; Definitely prefer study drug over prior treatment = 1, Slightly prefer study drug = 2, No preference = 3, Slightly prefer prior treatment = 4,
Definitely prefer prior treatment = 5. Patient willingness assessment; Would definitely use study drug again = 1, Might use study drug again = 2, Not sure = 3,
Might not use study drug again = 4, Would definitely not use study drug again = 5.
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Figure 5 Relationship between the components of the IBD PRTI (all patients) including patient satisfaction (a), preference (b), and
willingness (c) versus the Mayo endoscopy score. IBD PRTI item scores: Patient satisfaction assessment; Extremely dissatisfied with study
drug = 1, Dissatisfied with study drug = 2, Neither satisfied nor dissatisfied with study drug = 3, Satisfied with study drug = 4, Extremely satisfied
with study drug = 5. Patient preference assessment; Definitely prefer study drug over prior treatment = 1, Slightly prefer study drug = 2, No
preference = 3, Slightly prefer prior treatment = 4, Definitely prefer prior treatment = 5. Patient willingness assessment; Would definitely use study
drug again = 1, Might use study drug again = 2, Not sure = 3, Might not use study drug again = 4, Would definitely not use study drug again = 5.
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(P < 0.0001; patient preference assessment), 0.69 (P < 0.0001;
patient satisfaction assessment), and 0.60 (P < 0.0001; patient
willingness assessment) (Additional file 5).
Patients achieving endoscopic remission (Mayo endos-
copy score of 0) were significantly different from other pa-
tients (Mayo endoscopy score of 1, 2, or 3) on all IBD PRTI
components. Those differences were: 1.2 points (P < 0.0001;
Patient Preference Assessment), 1.4 points (P <0.0001; Pa-
tient Satisfaction Assessment), and 1.2 points (P < 0.0001;
Patient Willingness Assessment) if a model with imposed
linear relationship between IBD PRTI item score and Mayo
endoscopy score was used. If a model with Mayo endos-
copy score as a categorical predictor was used, those differ-
ences were: 1.2 points (P < 0.0001; Patient Preference
Assessment), 1.3 points (P < 0.0001; Patient Satisfaction
Assessment), and 1.0 points (P < 0.0001; Patient Willing-
ness Assessment). Correlations at Week 8 between IBD
PRTI item score and Mayo endoscopy score were moder-
ate: 0.47 (P < 0.0001; Patient Preference Assessment), 0.56
(P < 0.0001; Patient Satisfaction Assessment), and 0.44
(P < 0.0001; Patient Willingness Assessment) (Figure 5).
Discussion
We have reported the first detailed and comprehensive set
of PRO results on the use of tofacitinib in patients with
moderately-to-severely active UC. The results showed thatshort-term treatment with tofacitinib was associated with
statistically significant improvement in HRQoL and pa-
tient preferences for the study medication compared with
placebo. Improvements in HRQoL were dose-dependent
and, at the maximum dose of tofacitinib examined (15 mg
BID), the adjusted mean change in IBDQ total score be-
tween baseline and Week 8 was statistically significantly
greater compared with placebo. These results support the
clinical efficacy data reported previously from this Phase
II study, whereby patients with moderately-to-severely
active UC treated with tofacitinib were more likely to
achieve clinical response and remission, and endoscopic
response and remission, than those receiving placebo [7].
Our results are consistent with significant improvements
in PROs for patients treated with tofacitinib reported from
RCTs in other chronic inflammatory conditions, such as
rheumatoid arthritis [17,18] and psoriasis [19].
Relationship between PROs and the Mayo scores
The observed approximately linear relationship between
the PROs of the IBDQ and the IBD PRTI with the Mayo
scoring system for assessing clinical response demon-
strated the clinical relevance of the IBDQ and the IBD
PRTI in patients with moderately-to-severely active UC.
Interestingly, we also observed statistically significant
moderate to large correlations between the two domains
of Mayo score being considered as PROs, namely stool
Panés et al. BMC Gastroenterology  (2015) 15:14 Page 9 of 10frequency and rectal bleeding, and the IBDQ bowel do-
main subscore. Relationships between Mayo scores and
both PRO measurements were stable, in the right direc-
tion (reflecting benefit to the patient), and approximately
linear. Disease severity is reportedly the most important
factor influencing HRQoL in patients with UC [20,21],
and the results we report provide quantitative evidence
that reducing the signs and symptoms of UC with tofaciti-
nib treatment improves patients’ HRQoL. These results
also prove the responsiveness of IBDQ score and PRTI
items to therapeutic interventions. The relationships also
provide an estimate of the magnitude of improvement; for
example, a 1-point change on the total Mayo score corre-
sponded, on average, to a change (improvement) of 8.0
(P < 0.0001) points in the total IBDQ score. Furthermore,
our results also suggest mucosal healing should be a
therapeutic objective in patients with UC as patients
achieving endoscopic remission (Mayo endoscopy sub-
score of 0) had significantly different IBDQ and IBD PRTI
component scores compared with patients with persistent
endoscopic disease activity.
Our results further support the use of PROs for assess-
ment of drug efficacy. However, the low specificity of the
IBDQ at the individual level to identify patients achieving
remission defined by the Mayo score, indicate that PROs
could be used as complementary endpoints to endoscopic
or composite (clinical and endoscopic) scores.
IBD PRTI
Patient choice of treatment is a central feature of IBD
healthcare, and the IBD PRTI survey was specifically de-
signed to determine a patient’s treatment preference. We are
not aware of any existing IBD instrument/tool that captures
the important outcome of patient preference, and as such,
the IBD PRTI may have a future role as a useful indicator of
patient preference. We believe the trial we report is the first
trial in patients with UC to incorporate this particular PRO
and it was interesting to observe the approximate linear as-
sociations of the IBDQ with the Mayo scoring system were
also replicated by the associations of the IBD PRTI survey
with the Mayo scoring system. The development of novel
PRO tools for investigating UC is warranted because current
outcomes capture only a portion of the impact of the disease
on patients’ lives and may not accurately measure a patient’s
experience with UC [22].
Study limitations
The limitations of our analyses are that they were based on
a relatively small sample size from a single clinical trial that
focused on patients with moderately-to-severely active dis-
ease. Also, the duration of the study was short, and the
long-term benefit of tofacitinib on PROs remains to be
evaluated. Future analyses from larger ongoing Phase III
RCTs in UC (ClinicalTrials.gov identifiers: NCT01470612,NCT01458574, NCT01465763, and NCT01458951) will be
performed to corroborate and expand our findings.
Conclusions
Short-term treatment with tofacitinib was associated with
statistically significant dose-dependent improvement in
HRQoL and patient preference for the study medication.
The results support the clinical efficacy and safety data pre-
viously reported for this Phase II study [7] and reinforce
the rationale for continued investigation into the use of
tofacitinib in the treatment of patients with moderately-to-
severely active UC. In utilizing clinical efficacy data, we
showed a strong, approximately linear relationship between
the IBDQ, the IBD PRTI, and the Mayo scoring system,
and also between the IBDQ bowel function domain sub-
score and the IBD PRTI, thus supporting the clinical rele-
vance and validity of these PROs. Additionally, IBDQ and
IBD PRTI scores were shown to be significantly different
for patients achieving endoscopic remission compared with
those who did not.
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Additional file 1: IBD remission status (endoscopic remission vs
IBDQ remission [total score ≥170]). Relationship between endoscopic
remission and IBDQ remission.
Additional file 2: Institutional review board that approved the
study. Full names of every Institutional review board that approved the
study in each center.
Additional file 3: Inflammatory Bowel Disease Patient-Reported
Treatment Impact. Components of the IBD Patient-Reported Treatment
Impact questionnaire. Each of the three questions (except the question
on previous treatment, which was informational only) was scored on a
5-point scale.
Additional file 4: Patient disposition. patient disposition in the study.
Additional file 5: Relationship between Patient-Reported Treatment
Impact and clinical disease activity in ulcerative colitis. Relationship
between the components of the IBD Patient-Reported Treatment Impact
(all patients) versus the Mayo partial score. IBD PRTI item scores: Patient
satisfaction assessment; Extremely dissatisfied with study drug = 1,
Dissatisfied with study drug = 2, Neither satisfied nor dissatisfied with
study drug = 3, Satisfied with study drug = 4, Extremely satisfied with
study drug = 5. Patient preference assessment; Definitely prefer study
drug over prior treatment = 1, Slightly prefer study drug = 2, No
preference = 3, Slightly prefer prior treatment = 4, Definitely prefer prior
treatment = 5. Patient willingness assessment; Would definitely use study
drug again = 1, Might use study drug again = 2, Not sure = 3, Might not
use study drug again = 4, Would definitely not use study drug again = 5.
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